Back to mobile site

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

September 24, 2026 12:16 PM EDT Send to a Friend
BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login